Novartis CEO Vas Narasimhan stated the company will not join the weight loss drug market, focusing instead on unique areas like treatments for secondary effects of weight loss. Avoiding direct competition with major obesity drugmakers, Narasimhan highlighted Novartis’ research in reducing side effects and retaining muscle mass. The company aims to target winning areas like Alzheimer’s, Huntington’s, Parkinson’s, and cancer therapies, particularly its radioligand therapies, expecting to build a $20 billion business and maintain a distinct position in the market.
Full Article
Trump’s Tariffs Could Help Tesla, by Hurting Its Rivals More
President Trump's new tariffs on Chinese goods and threats of a trade war with Mexico and Canada have potential implications for Tesla, as the electric car maker is less vulnerable due to self-sufficient supply chains in the US and China. While Tesla's competitors may suffer more from the tariffs, the company remains at risk if relations with China deteriorate. The trade war and Trump's policies could impact Tesla's sales in China and Europe, although its...
Read more